GlassScriptPhysician profile
Kimberly Hurley
NPI 1851024004
$6,215.25
in general payments reported to CMS, 2019-2025
23 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $923 · 2023: $1,807 · 2024: $1,593 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,283 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,282.77 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,043.82 | 2022-2025 | |
| Lundbeck LLC | $1,154.45 | 2022-2025 | Vyepti |
| Pfizer INC. | $604.18 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $436.29 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $335.93 | 2022-2024 | Reyvow, Emgality, Mounjaro |
| Amgen INC. | $215.10 | 2022-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $212.38 | 2022-2025 | Ajovy |
| Axsome Therapeutics, INC. | $205.47 | 2022-2025 | Symbravo, Sunosi |
| Impel Pharmaceuticals INC. | $176.19 | 2023 | Trudhesa |
| Harmony Biosciences LLC | $175.41 | 2022-2025 | Wakix |
| Tonix Medicines, INC. | $141.02 | 2024-2025 | Zembrace Symtouch |
| Biohaven Pharmaceutical Holding Company LTD. | $137.97 | 2022 | |
| Scilex Pharmaceuticals INC. | $70.91 | 2023 | Ztlido |
| Merck Sharp & Dohme LLC | $59.16 | 2023 | Belsomra |
| Upsher-Smith Laboratories LLC | $39.01 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $33.59 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $32.49 | 2023 | |
| Supernus Pharmaceuticals, INC. | $28.28 | 2022 | |
| Octapharma USA, INC. | $27.69 | 2024 | Octagam Immune Globulin (Human) |
| Inspire Medical Systems, INC. | $25.96 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $23.24 | 2024 | Airsupra |
| Eisai INC. | $22.66 | 2024 | |
| Neurocrine Biosciences, INC. | $14.05 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.